Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CamRelief: Camrelizumab in early TNBC
NCT04613674Phase 3Completed
- Sponsor
- Hengrui
- Start
- Dec 2020
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Hengrui. Started Dec 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04613674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613674.